Business: Dr. Reddy's is trying to bring the Sputnik M vaccine for teenagers to India

Deepak Sapra CEO API and Services Dr. Reddy’s, also said the company is fully geared to make Molnupiravir, a COVID-19 drug both API and Formulations, at its facilities, even as it approached World Health organization for the prequalification of the drug. “Sputnik M is a sputnik for adolescents. In Russia, Sputnik M has been given the approval by the regulator for children in the 12 to 18 years old group. The same data has been made available here. We are in the process of translating the data and we will be having a conversation with the regulator on this data within the next few months,” Sapra told reporters.

Dr Reddy’s Laboratories announced on Friday that it is in talks with the Indian pharma authority about bringing Russia’s Sputnik M, a COVID-19 vaccine for children aged 12 to 18, to India. A senior executive of the pharma producer stated Phase 3 clinical trial data of Russia’s single dosage COVID-19 vaccine Sputnik Light has been submitted to the regulator and is awaiting clearance during a press conference following the company’s Q3 results.

Suggestion For You:
Best Bang and Olufsen Headphones
The Best Wireless Gaming Headsets

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

He further said the company may probably conduct another round of clinical trials in India if the Indian regulator says so. Russian Direct Investment Fund (RDIF) last month said it has applied for the registration of Sputnik M, to the Indian regulator for approval. The sovereign wealth fund said Russia’s Health Ministry registered Sputnik M on November 24, 2021. Replying to query, he said the clinical trials for the Sputnik Light in India are over and the data was submitted to the Drug Controller General of India. Replying to query, he said the clinical trials for the Sputnik Light in India are over and the data was submitted to the Drug Controller General of India.

“It has demonstrated efficacy which is consistent and in line with the result that we have seen in the global trials which we have conducted in Russia. What we conducted in India is safety and immunogenicity studies,” Sapra said. On Molnupiravir, the official said in this current wave Omicron is the dominant variant and it has seen relatively lower hospitalizations. However, the company will continue to be ready for the COVID-19 drug to be made available for India and 103 countries for which it has rights.

Disclaimer: If you need to edit or update this news from compsmag then kindly contact us Learn more